Cardiovascular disease in type 2 diabetes: Challenge for treatment and prevention

Journal of Internal Medicine

Volumn 249, Issue 3, 2001, Pages 225-235

  Laakso, M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cardiovascular disease; Cardiovascular risk factors; Coronary heart disease; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FIBRINOLYTIC AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NITRENDIPINE; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; PREDIABETIC STATE; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 0035013610     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00789.x     Document Type: Review

References (52)

1. Diabetes and atherosclerosis: An epidemiologic view
2. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
3. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
4. Early abnormalities in coronary heart disease risk factors in relatives of subjects with non-insulin-dependent diabetes
5. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study
6. Epidemiology of macrovascular disease in diabetes
7. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95 783 individuals followed for 12.4 years
8. Epidemiology of diabetic dyslipidemia
9. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial
10. Insulin resistance and coronary heart disease
11. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men
12. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes
13. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23)
14. Hyperglycemia and cardiovascular disease in type 2 diabetes
15. Hyperglycemia and microvascular and macrovascular disease in diabetes
16. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM
17. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
18. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
19. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial
20. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
21. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes. The Post Coronary Artery Bypass Graft Trial
22. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
23. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
24. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
25. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
26. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
27. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
28. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
29. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
30. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
31. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment
32. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33
33. Impact of diabetes on mortality after the first myocardial infarction
34. Diabetes and decline in heart disease mortality in US adults
35. Metoprolol In Acute Myocardial Infarction (MIAMI): A randomised placebo-controlled international trial
36. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction
37. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: Retrospective data from two large studies
38. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease
39. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
40. Randomozed trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction
41. Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients
42. Effect of the ACE-inhibitor lisinopril on mortality in diabetic patients with acute myocardial infacrtion: The data from the GISSI-3 Study
43. Diabetes mellitus, a predictor of morbidity and mortality in the Studies Of Left Ventricular Dysfunction (SOLVD) Trials and Registry
44. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
45. Glycometa-bolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myo-cardial Infarction (DIGAMI) study
46. Influence of diabetes on 5-year mortality, morbidity in a randomized trial comparing CABG, and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation
47. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction
48. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study
49. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes
50. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study
51. Report of the National Cholesterol Education Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
52. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy